Cannabinoidomics – An analytical approach to understand the effect of medical Cannabis treatment on the endocannabinoid metabolome

Berman, Paula; Sulimani, Liron; Gelfand, Anat; Amsalem, Keren; Lewitus, Gil M.; Meiri, David

doi:10.1016/j.talanta.2020.121336

Cited by 31 publications

(23 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Leweke et al [ 21 ] have shown that a two-week treatment with CBD increased circulating levels of AEA, PEA, and OEA in the serum of schizophrenia patients. In a recently published paper by our group [ 22 ], we also showed that different high-CBD cannabis extracts modulate the levels of eCB and eCB-like lipids in mouse brains and serum.…”

Section: Introductionmentioning

confidence: 70%

“…To further test the possibility that a flow of ectopic Phytocannabinoids in the blood of cannabis users may modulate the eCBS and alter their levels, we analyzed a comprehensive panel of serum eCB and eCB-like lipids and measured their levels in cancer patients before and after immunotherapy from both cannabis users and nonusers. eCB and eCB-like serum concentrations were monitored in blood samples using a novel liquid chromatography-mass spectrometric (LC/MS) method recently developed and validated by our group [ 22 ] ( Table 4 ). Four lipids [ N -eicosapentaenoyl ethanolamide (EPEA), O -arachidonoyl ethanolamide (O-AEA), N -arachidonoyl alanine (A-Ala), and N -arachidonoyl gamma-aminobutyric acid (A-GABA)] resulted below the detection limits in all patients and were excluded from this study.…”

Section: Resultsmentioning

confidence: 99%

“…Analysis of eCB and eCB-like lipids was performed according to a method recently developed and validated by our group [ 22 ]. Briefly, liquid chromatography-mass spectrometric (LC/MS) grade acetonitrile, methanol, and water for the mobile phase and high-performance liquid chromatography (HPLC) grade methanol, acetonitrile, and water for sample preparation were obtained from Mercury Scientific and Industrial Products Ltd. (Rosh Haayin, Israel).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome

Bar-Sela

Bar‐Sela

Campisi-Pinto

et al. 2020

Cancers

Self Cite

124

View full text Add to dashboard Cite

Cannabis or its derivatives are widely used by patients with cancer to help with cancer symptoms and treatment side effects. However, cannabis has potent immunomodulatory properties. To determine if cannabis consumption during immunotherapy affects therapy outcomes, we conducted a prospective observatory study including 102 (68 immunotherapy and 34 immunotherapy plus cannabis) consecutive patients with advanced cancers who initiated immunotherapy. Cannabis consumption correlated with a significant decrease in time to tumor progression and overall survival. On the other hand, the use of cannabis reduced therapy-related immune-related adverse events. We also tested the possibility that cannabis may affect the immune system or the tumor microenvironment through the alteration of the endocannabinoid system. We analyzed a panel of serum endocannabinoids (eCBs) and eCB-like lipids, measuring their levels before and after immunotherapy in both groups. Levels of serum eCBs and eCB-like lipids, before immunotherapy, showed no significant differences between cannabis users to nonusers. Nevertheless, the levels of four eCB and eCB-like compounds were associated with patients’ overall survival time. Collectively, cannabis consumption has considerable immunomodulatory effects, and its use among cancer patients needs to be carefully considered due to its potential effects on the immune system, especially during treatment with immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 70%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome

Bar-Sela

Bar‐Sela

Campisi-Pinto

et al. 2020

Cancers

Self Cite

124

View full text Add to dashboard Cite

show abstract

“…Endocannabinoids and related NAEs are produced on demand and play a crucial regulatory role in metabolic processes, behavior, and immunity. Under healthy conditions these lipid mediators are most abundant in the brain and barely found in circulation and peripheral tissues [ 55 ]. During various pathological conditions of the CNS the profiles of eCBs and their congeners undergo significant changes, which is associated with the inflammation-modulating, analgesic, and neuroprotective activity of these compounds (summarized in Table 2 ).…”

Section: The Endocannabinoid Systemmentioning

confidence: 99%

Neuroprotective and Immunomodulatory Action of the Endocannabinoid System under Neuroinflammation

Kasatkina

Rittchen

Sturm

2021

IJMS

View full text Add to dashboard Cite

Endocannabinoids (eCBs) are lipid-based retrograde messengers with a relatively short half-life that are produced endogenously and, upon binding to the primary cannabinoid receptors CB1/2, mediate multiple mechanisms of intercellular communication within the body. Endocannabinoid signaling is implicated in brain development, memory formation, learning, mood, anxiety, depression, feeding behavior, analgesia, and drug addiction. It is now recognized that the endocannabinoid system mediates not only neuronal communications but also governs the crosstalk between neurons, glia, and immune cells, and thus represents an important player within the neuroimmune interface. Generation of primary endocannabinoids is accompanied by the production of their congeners, the N-acylethanolamines (NAEs), which together with N-acylneurotransmitters, lipoamino acids and primary fatty acid amides comprise expanded endocannabinoid/endovanilloid signaling systems. Most of these compounds do not bind CB1/2, but signal via several other pathways involving the transient receptor potential cation channel subfamily V member 1 (TRPV1), peroxisome proliferator-activated receptor (PPAR)-α and non-cannabinoid G-protein coupled receptors (GPRs) to mediate anti-inflammatory, immunomodulatory and neuroprotective activities. In vivo generation of the cannabinoid compounds is triggered by physiological and pathological stimuli and, specifically in the brain, mediates fine regulation of synaptic strength, neuroprotection, and resolution of neuroinflammation. Here, we review the role of the endocannabinoid system in intrinsic neuroprotective mechanisms and its therapeutic potential for the treatment of neuroinflammation and associated synaptopathy.

show abstract

“…An increasing number of studies use mass spectral libraries (i.e. NIST20 library) [47] or in-house databases [48] for the annotation of the Cannabis metabolome [47], in a metabolomic approach variously referred to as Cannabinomics, Cannabinoidomics, or Phytocannabinomics [49][50][51]. We used several mass spectral libraries and three levels of annotations (see above in 2.3), allowing in most cases an annotation of level 2 according to the metabolomic standard initiative [52].…”

Section: Cannabinomics Reveals Major Discriminant Compounds Between Cannabis Varietiesmentioning

confidence: 99%

Cannabinoids vs. whole metabolome: relevance of cannabinomics in analyzing Cannabis varieties

Vásquez-Ocmín

Marti

Bonhomme

et al. 2021

Preprint

View full text Add to dashboard Cite

Cannabis sativa has a long history of domestication both for its bioactive compounds and its fibers. This has produced hundreds of varieties, usually characterized in the literature by chemotypes, with Δ9-THC and CBD content as the main markers. However, chemotyping could also be done based on minor compounds (phytocannabinoids and others). In this work, a workflow, which we propose to name cannabinomics, combines mass spectrometry of the whole metabolome and statistical analysis to help differentiate C. sativa varieties and deciphering their characteristic markers. By applying this cannabinomics approach to the data obtained from 20 varieties of C. sativa (classically classified as chemotype I, II, or III), we compared the results with those obtained by a targeted quantification of 11 phytocannabinoids. Cannabinomics can be considered as a complementary tool for phenotyping and genotyping, allowing the identification of minor compounds playing a key role as markers of differentiation.

show abstract

Cannabinoidomics – An analytical approach to understand the effect of medical Cannabis treatment on the endocannabinoid metabolome

Cited by 31 publications

References 47 publications

Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome

Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome

Neuroprotective and Immunomodulatory Action of the Endocannabinoid System under Neuroinflammation

Cannabinoids vs. whole metabolome: relevance of cannabinomics in analyzing Cannabis varieties

Contact Info

Product

Resources

About